Camptosar: profile and news

NCCN Announces Important Updates to Ovarian Cancer Clinical ...  06 Mar 2006
...modalities for ovarian cancer to include anastrazole (Arimidex, AstraZeneca), bevacizumab (Avastin, Genentech), irinotecan (Camptosar, Pfizer), ifosfamide (Ifex ... - Genetic Engineering News,

Test Now Available to Guide Dosing of Camptosar® in Colorectal ...  Feb 14, 2006
...available that detects variants within the UGT1A1 gene; these variants are associated with severe side effects from treatment with Camptosar® (irinotecan) for ... - Cancer Consultants (press release),

FDA gives greenlight for new treatment of head and neck cancer  Mar 4, 2006
Erbitux was previously approved by the FDA to be used in combination with Camptosar (irinotecan) for the treatment of colorectal cancer that no longer responds ... - News-Medical.net,

Addition of Erbitux® to Radiation Therapy Improves Survival in ...  Feb 22, 2006
Erbitux is currently FDA-approved in combination with Camptosar® (irinotecan) for the treatment of colorectal cancer that has stopped responding to irinotecan ... - Cancer Consultants (press release),

FDA Approves Erbitux® For Treatment of Head and Neck Cancer  Mar 2, 2006
Erbitux was previously FDA-approved to be used in combination with Camptosar® (irinotecan) for the treatment of colorectal cancer that has stopped responding ... - Cancer Consultants (press release),

Bristol-Myers Squibb Seeks To Expand Access To Its Most Recently ...  Feb 19, 2006
Reyataz should not be taken with the following medicines: ergot medicines, Versed®, Halcion®, Orap®, Propulsid®, Camptosar®, Crixivan®, Mevacor®, Zocor ... - Medical News Today (press release),

New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) ...  Feb 9, 2006
REYATAZ should not be taken with the following medicines: ergot medicines, Versed(R), Halcion(R), Orap(R), Propulsid(R), Camptosar(R), Crixivan(R), Mevacor(R ... - Finanzen.net,

LabCorp(R) Now Offering UGT1A1 Pharmacogenetic Test for Dosing ...  Feb 13, 2006
UGT1A1 gene associated with excessive toxicity in individuals treated with the late-stage colorectal cancer drug irinotecan hydrochloride (Camptosar(R)). The ... - CNW Telbec (Communiqués de presse),

Addition of Erbitux® to Radiation Therapy Improves Survival in ...  09 Feb 2006
Erbitux is currently FDA-approved in combination with Camptosar® (irinotecan) for the treatment of colorectal cancer that has stopped responding to irinotecan ... - Cancer Consultants (press release),

New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) ...  09 Feb 2006
REYATAZ should not be taken with the following medicines: ergot medicines, Versed®, Halcion®, Orap®, Propulsid®, Camptosar®, Crixivan®, Mevacor®, Zocor ... - Yahoo! News (press release)

ASCO-GI: Neoadjuvant Chemoradiation Improves Esophageal Cancer ...  Jan 27, 2006
...drugs used," said medical oncologist David Ilson, MD, of Memorial Sloan-Kettering Cancer Center in New York, who has been using a Camptosar (irinotecan)-based ... - MedPage Today,

Pfizer Fourth-Quarter and Full-Year 2005 Financial Results Reflect ...  Jan 19, 2006
3 VIAGRA 430 469 (8) 212 248 (15) 218 221 (1) DETROL/ DETROL LA 283 285 (1) 193 207 (7) 90 78 15 - ONCOLOGY 497 453 10 167 182 (8) 330 271 22 CAMPTOSAR 237 189 ... - PR Newswire (press release),

Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice ...  Jan 17, 2006
...of the sales force in 2000, led a 90-member sales force, and shared responsibility for the sales success of products that included Camptosar(R) (irinotecan ... - PR Newswire (press release),

Genzyme Launches Colorectal Cancer Test to Determine Appropriate ...  Dec 6, 2005
Assay for colorectal cancer patients in the North American market who are being considered for, or currently taking, the chemotherapy Camptosar® (irinotecan). ... - Yahoo! News (press release)

Beware Of Fake Cures & Other Medical Frauds On The Web  Nov 28, 2005
They actually say their pill is Camptosar, a Pfizer drug used for treatming colon cancer, but it’s clearly not Camptosar. According ... - PR Web (press release),

Universal Adjuvant Chemotherapy Use Is Elusive for Advanced Colon ...  Dec 6, 2005
...and Wellcovorin (leucovorin), but the researchers suggested that studies are needed to see if newer regimens - using such drugs as Camptosar (irinotecan) or ... - MedPage Today,

Phase II Trial of Panitumumab Plus FOLFIRI for Metastatic ...  Nov 11, 2005
Researchers from Northwestern Universityhave reported that the combination of the panitumumab (ABX-EGF) and 5-fluorourcil, Camptosar® (irinotecan), and ... - Cancer Consultants (press release),

Oncologist settles Medicare fraud suit  Nov 8, 2005
2001. “Let’s say the drug is Camptosar,� Ledford said, referring to an intravenous drug used to treat colon or rectum cancer. ... - Columbia Missourian,

Doctor's federal fraud trial begins  Nov 30, 2005
Moon also took the unusual step of mixing chemotherapy drugs — including Taxol and Camptosar — herself, instead of leaving that job to a pharmacist or nurse ... - Gallatin News Examiner,

Biotech Roars Back in November  Dec 1, 2005
UGT1A1 pharmacogenetic test, designed to detect select polymorphisms associated with adverse reactions to Pfizer's chemotherapy drug, Camptosar, the company's ... - PR Newswire (press release),

Doctor says fraud allegations stem from irate workers  Dec 1, 2005
Moon also mixed chemotherapy drugs — including Taxol and Camptosar — herself instead of leaving that job to a pharmacist or nurse and did not mix full doses ... - Southern Standard,

New age of medicine: Treatment tailored to your DNA, enzymes  Nov 13, 2005
Since June, the label for Camptosar, a Pfizer drug for colon cancer, has advised doctors that a lower starting dose may be appropriate for the 10 percent of ... - San Francisco Chronicle,

48-Week Clinical Trial Data Provides Information Regarding ...  Nov 18, 2005
REYATAZ should not be taken with the following medicines: ergot medicines, Versed®, Halcion®, Orap®, Propulsid®, Camptosar®, Crixivan®, Mevacor®, Zocor ... - Yahoo! News (press release)

Oncologist agrees to surrender license  Nov 9, 2005
...were instead re-used and administered to additional patients," said Graves, noting that drugs such as Etoposide, 5-FU, Proleukin and Camptosar are designated ... - Hannibal Courier Post,

48-Week Clinical Trial Data Provides Information Regarding ...  Nov 18, 2005
REYATAZ should not be taken with the following medicines: ergot medicines, Versed(R), Halcion(R), Orap(R), Propulsid(R), Camptosar(R), Crixivan(R), Mevacor(R ... - Biotech Intelligence (press release),

Oral Hycamtin® Better than Best Supportive Care for Recurrent ...  Nov 14, 2005
Due to the activity against SCLC demonstrated with topoisomerase I-inhibiting agents such as Hycamtin or Camptosar® (irinotecan), researchers from the UK ... - Cancer Consultants (press release),

Phase II Trial of Panitumumab Plus FOLFIRI for Metastatic ...  Nov 8, 2005
One commonly used combination is referred to as FOLFIRI. It is the combination of 5-fluorourcil, Camptosar® (irinotecan), and leucovorin. ... - Cancer Consultants (press release),

FDA Safety Labeling Changes: Camptosar, Keppra, Prempro/Premphase  Sep 21, 2005
On July 7, the FDA approved revisions to the safety labeling for irinotecan HCl injection (Camptosar, made by Pfizer, Inc.) to recommend reduced dosing in ... - Medscape (subscription)

One To Watch  Oct 5, 2005
Additionally, the broker notes the Camptosar drug used to treat such cancer is very hard on the gastrointestinal system, something the HyACT delivery platform ... - Australasian Investment Review (subscription),

Pro-Pharmaceuticals Announces Final Phase I Results  Oct 6, 2005
..."In addition to our positive Phase I results with 5-FU, we have had positive preclinical results with irinotecan (Camptosar(R)-Pfizer, Inc., NYSE:PFE ... - Genetic Engineering News,

Imclone's Erbitux Gets Canadian Approval for Colon Cancer Use  Sep 15, 2005
Erbitux can be used in combination with Pfizer Inc.'s Camptosar by patients whose treatment has lost effectiveness, Imclone said in a statement distributed by ... - Bloomberg

Imclone's Erbitux Approved in Canada for Colon Cancer (Update3  Sep 18, 2005
It is given either with Pfizer Inc.'s Camptosar or alone in patients who can't take the older cancer drug, the New York-based companies said today in a ... - Borsa-Italia.Net,

National business briefs  Sep 16, 2005
Erbitux can be used in combination with Pfizer Inc.'s Camptosar by patients whose treatment has lost effectiveness, Imclone said in a statement. ... - NorthJersey.com,

Gain Insight into the Current Challenges and Commercial ...  Sep 22, 2005
This is most prominent due to the introduction of three novel cytotoxic agents - Xeloda, Camptosar, and Eloxatin - and the recent approval of the two ... - Business Wire (press release),

Taxol®, Ifex® and Platinol® Effective Second-Line Therapy for ...  Sep 22, 2005
Japanese researchers have Camptosar® (irinotecan) combined with either Platinol or nedaplatin (NDP), a derivative of Platinol results in response rates of 50 ... - Cancer Consultants (press release),

FDA Approves Gene Test to Help in Dosing of Colorectal Cancer Drug  Aug 24, 2005
24-The FDA has approved a genetic test that will allow clinicians to maximize efficacy and safety of Camptosar (irinotecan), a drug used to treat colorectal ... - MedPage Today,

Enzon names Dr. Ivan Horak Chief Scientifc Officer  Sep 7, 2005
President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar® for metastatic ... - Chemie.de (press release),

Xelox Yields Impressive Survival in Pre-Treated Metastatic ...  Aug 26, 2005
Initial treatment often includes chemotherapy regimens consisting of Camptosar® (irinotecan), Eloxatin® (oxaliplatin), or Fluoroplex® (5-fluorouracil). ... - Cancer Consultants (press release),

UPDATE 2-US FDA clears Third Wave genetic blood test  Aug 22, 2005
Invader UGT1A1 Molecular Assay, so far has only been shown to work with Pfizer Inc.'s (PFE.N: Quote, Profile, Research) colon cancer drug Camptosar, but future ... - Reuters

US FDA clears Third Wave genetic blood test  Aug 22, 2005
...said the test, called the Invader UGT1A1 Molecular Assay, so far has only been shown to work with Pfizer Inc.'s colon cancer drug Camptosar, but future data ... - Reuters

Pharmacogenetic cancer test receives FDA clearance  Aug 23, 2005
The genetic test detects a change in the DNA of a gene that encodes for a protein involved in the metabolism of the chemotherapy drug Camptosar (irinotecan). ... - in-PharmaTechnologist,

Twelve Hour Infusion of Eloxan® plus Xeloda® Effective Regimen ...  Aug 30, 2005
Combination chemotherapy regimens including Camptosar and Eloxan improve responses and prolong survival in metastatic colorectal cancer compared to Fluoroplex ... - Cancer Consultants (press release),

'Smart tests' can aid therapy  Aug 27, 2005
...a variation in a patient's genetic makeup that would make them more likely to experience the side effects associated with the chemotherapy drug Camptosar. ... - Minneapolis Star Tribune (subscription),

Third Wave Receives FDA Clearance of Pharmacogenetic Test  Aug 22, 2005
R) UGT1A1 test is cleared for use to identify patients who may be at increased risk of adverse reaction to the chemotherapy drug Camptosar (irinotecan) by ... - PR Newswire (press release),

Erbitux Improves Responses in Refractory Head and Neck Cancer  Aug 24, 2005
Erbitux is currently FDA-approved in combination with the chemotherapy agent Camptosar® (irinotecan) for the treatment of colorectal cancer that has stopped ... - Cancer Consultants (press release),

FDA Approvals: Invader UGT1A1, SelectSecure Model 3830, Duet ...  Aug 26, 2005
Inc.) for use in identifying patients that may be at increased risk of adverse reactions to the chemotherapy drug irinotecan HCl (Camptosar, made by Pfizer, Inc ... - Medscape (subscription)

New test aids treatment of colorectal cancer  Aug 24, 2005
...of myDNA.com's Medical Advisory Board and Austin oncologist believes the test will "help doctors determine if patients receiving the drug Camptosar are at ... - myDNA.com,

Pfizer seeks approval for cancer drug  Aug 10, 2005
Its few cancer treatments include three also acquired from the Pharmacia merger -- Aromasin and Ellence for breast cancer and Camptosar for colorectal cancer. ... - Reuters

Research and Markets: Generic Adversity Facing Major Cytotoxics  Aug 15, 2005
Case studies examining Sanofi-Aventis's Eloxatin with Pfizer's Camptosar for the treatment of colorectal cancer and its reliance on cytotoxic sales are also ... - Business Wire (press release),

FDA Approves New Genetic Blood Tests  Aug 23, 2005
...and Drug Administration says the Invader UGT1A1 Molecular Assay has so far only been shown to work with Pfizer Inc's colon cancer drug Camptosar, but future ... - All Headline News

The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR. The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.

Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect. However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.

Hyperglycemia has also been reported in patients receiving CAMPTOSAR. Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR. It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.

The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.

It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.

In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.

Drug-Laboratory Test Interactions

There are no known interactions between CAMPTOSAR and laboratory tests.